Diltiazem tablets/capsules bulk supplier for pharma manufacturers

Diltiazem Tablets/Capsules Suppliers & Bulk Manufacturers

Available Forms: Tablet/Capsules

Available Strengths: IR: 30 mg, 60 mg, 90 mg, 120 mg; modified-release: 60 mg to 420 mg

Reference Brands: Cardizem (US)

Diltiazem immediate-release tablets and modified-release tablets and capsules, a non-dihydropyridine calcium channel blocker for angina, hypertension and rate control, offered to importers, distributors, hospitals and tender buyers.

Get Enquiry / Request Bulk Quote

Usually answered within 48 hours | GMP documents shared before you commit

Manufacture or export Diltiazem Tablets/Capsules? List it or send an offer →

Product Description:

Diltiazem is a non-dihydropyridine calcium channel blocker of the benzothiazepine type. It slows calcium entry into heart muscle and artery walls, so arteries widen, the heart rate falls slightly and conduction through the AV node slows. This page covers immediate-release tablets such as 60, 90 and 120 mg, plus modified-release tablets and capsules in the higher strengths listed. Plain tablets are taken three times a day; modified-release forms spread the dose over 12 or 24 hours for long-term care.

Diltiazem is used to prevent angina, including coronary spasm, and its modified-release forms are used for hypertension. Prescribers also use it for rate control in atrial fibrillation. It is avoided in second- or third-degree heart block without a pacemaker, sick sinus syndrome, marked bradycardia and heart failure with reduced ejection fraction. With a beta-blocker, watch for bradycardia and heart block. It inhibits CYP3A4 and raises levels of simvastatin and ciclosporin. Modified-release products release differently, so patients usually stay on one product.

Sourcing notes. State whether you need immediate or modified release, the strength and the dosing interval. For modified-release products, ask for the dissolution profile and the bioequivalence study against your market's reference product. Dossiers come in CTD or ACTD format, with stability data for your climatic zone, including Zone IVb for hot, humid markets. Packs should protect from moisture; storage is at room temperature, with no cold chain. It is prescription-only. Ask for a CoA per batch, the GMP certificate and a CoPP where needed.

Diltiazem Tablets/Capsules — third party manufacturing & bulk supply

Diltiazem Tablets/Capsules is available through PharmaTradz for wholesale and bulk supply as well as on a third party (contract) manufacturing basis. Buyers sourcing this product generally take one of three routes:

Wholesale / bulk supply Stock or scheduled supply from an existing manufacturer. The fastest route where the product is already registered in your market.

Third party manufacturing Manufactured to your specification and packed under your own brand and label — suits distributors and brand owners building a portfolio in their market.

Dossier licensing Where a CTD, EU-CTD or ACTD dossier exists it can often be licensed for filing in your name, compressing market entry from years to months.

Indicative minimum order quantity

Diltiazem Tablets/Capsules is supplied as Tablet/Capsules — an oral solid dosage form, so the indicative MOQ is 200,000 units. Actual MOQ is confirmed by the allocated manufacturer against your pack presentation and destination market. See full supply terms for dossier formats, market availability and shelf life.

Manufacturers of Diltiazem Tablets/Capsules listed on PharmaTradz hold site-level approvals across WHO-GMP, EU-GMP, USFDA, ANVISA and TGA, verified at onboarding.

Request a quote for Diltiazem Tablets/Capsules →

Usually answered within 48 hours, with matched manufacturers, indicative prices and document status.

Back to Listing

Frequently Asked Questions

Diltiazem tablets/capsules is listed as Tablet/Capsules in IR: 30 mg, 60 mg, 90 mg, 120 mg; modified-release: 60 mg to 420 mg. Further strengths and pack presentations are confirmed with the manufacturer at RFQ stage.

Diltiazem tablets/capsules is referenced against Cardizem (US). Reference brands are shown for identification only and remain the property of their respective trademark owners.